ArticleNanomedicine : nanotechnology, biology, and medicine2009
PEGylated PLGA nanoparticles for the improved delivery of doxorubicin.
Article in Nanomedicine : nanotechnology, biology, and medicine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 106 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
106 citing papers in PubMed, 335 citations in OpenAlex.
- Drug Polymer Nanoparticles: An Advancement in Biomedical Solutions and Targeted Drug Delivery.Drug design, development and therapy · 2026Review
- Amphiphilic mPEG-PLGA copolymer nanoparticles co-delivering colistin and niclosamide to treat colistin-resistant Gram-negative bacteria infections.Communications biology · 2025Article
- Mesoporous silica loaded with calcitonin gene-related peptide antagonist andFrontiers in molecular biosciences · 2025Article
- Nano-Bacillus Calmette-Guérin immunotherapies for improved bladder cancer treatment.Journal of Zhejiang University. Science. B · 2024Review
- Recent Advances in Micro- and Nano-Drug Delivery Systems Based on Natural and Synthetic Biomaterials.Polymers · 2023Review
- A potential paradigm in CRISPR/Cas systems delivery: at the crossroad of microalgal gene editing and algal-mediated nanoparticles.Journal of nanobiotechnology · 2023Review
- Nanoparticles in Medicine: Current Status in Cancer Treatment.International journal of molecular sciences · 2023Review
- Effect of Nanoparticle Weight on the Cellular Uptake and Drug Delivery Potential of PLGA Nanoparticles.ACS omega · 2023Article
- Curcumin-loaded mesoporous silica nanoparticles for drug delivery: synthesis, biological assays and therapeutic potential - a review.RSC advances · 2023Review
- Properties of Poly (Lactic-co-Glycolic Acid) and Progress of Poly (Lactic-co-Glycolic Acid)-Based Biodegradable Materials in Biomedical Research.Pharmaceuticals (Basel, Switzerland) · 2023Review
- PLGA Particles in Immunotherapy.Pharmaceutics · 2023Review
- Article
- Monoclonal antibody as a targeting mediator for nanoparticle targeted delivery system for lung cancer.Drug delivery · 2022Review
- Microbubble-Nanoparticle Complexes for Ultrasound-Enhanced Cargo Delivery.Pharmaceutics · 2022Review
- Biomaterial-targeted precision nanoparticle delivery to the injured spinal cord.Acta biomaterialia · 2022Article
- Naked and Decorated Nanoparticles Containing HInternational journal of molecular sciences · 2022Article
- High-Throughput Method for the Simultaneous Determination of Doxorubicin Metabolites in Rat Urine after Treatment with Different Drug Nanoformulations.Molecules (Basel, Switzerland) · 2022Article
- Surface conjugation of antibodies improves nanoparticle uptake in bronchial epithelial cells.PloS one · 2022Article
- Human induced pluripotent stem cell-derived platelets loaded with lapatinib effectively target HER2+ breast cancer metastasis to the brain.Scientific reports · 2021Article
- Morphologically Diverse Micro- and Macrostructures Created via Solvent Evaporation-Induced Assembly of Fluorescent Spherical Particles in the Presence of Polyethylene Glycol Derivatives.Molecules (Basel, Switzerland) · 2021Article
46 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
We hypothesize that the efficacy of doxorubicin (DOX) can be maximized and dose-limiting cardiotoxicity minimized by controlled release from PEGylated nanoparticles. To test this hypothesis, a unique surface modification technique was used to create PEGylated poly(lactic-co-glycolic acid) (PLGA) nanoparticles encapsulating DOX. An avidin-biotin coupling system was used to control poly(ethylene glycol) conjugation to the surface of PLGA nanoparticles, of diameter approximately 130 nm, loaded with DOX to 5% (wt/wt). Encapsulation in nanoparticles did not compromise the efficacy of DOX; drug-loaded nanoparticles were found to be at least as potent as free DOX against A20 murine B-cell lymphoma cells in culture and of comparable efficacy against subcutaneously implanted tumors. Cardiotoxicity in mice as measured by echocardiography, serum creatine phosphokinase (CPK), and histopathology was reduced for DOX-loaded nanoparticles as compared with free DOX. Administration of 18 mg/kg of free DOX induced a sevenfold increase in CPK levels and significant decreases in left ventricular fractional shortening over control animals, whereas nanoparticle-encapsulated DOX produced none of these pathological changes. FROM THE CLINICAL EDITOR: The efficacy of doxorubicin (DOX) may be maximized and dose-limiting cardiotoxicity minimized by controlled release from PEGylated nanoparticles. Administration of 18 mg/kg of free DOX induced a sevenfold increase in CPK levels and significant decreases in left ventricular fractional shortening in mice, whereas nanoparticle-encapsulated DOX produced none of these pathological changes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.